Efficiently networking European neurodegeneration research
NeuroNet logo


Start Date
End Date
IMI2 - Call 13
Grant agreement number

Type of Action: 
CSA (Coordination and Support Action)

IMI Funding
1 199 125
EFPIA in kind
1 010 000
Associated Partners
144 000
Total Cost
2 353 125


IMI’s growing neurodegenerative disorders (ND) portfolio is to get a new, dynamic platform – NEURONET – that will make it easier for the many projects to exploit synergies and connect the resources and needs of the different projects. NEURONET aims to be a key enabler and mediator across the portfolio, assisting in identifying gaps, multiplying impacts, enhancing visibility and ensuring coordination with related initiatives in Europe and worldwide. The mapping of ND actions and initiatives is among NEURONET’s objectives, as is providing coordination and support to the individual IMI projects, management support to the whole programme, and the identification and dissemination of best practices and learnings. Designed to take a different approach to typical Coordination and Support Actions (CSAs), NEURONET hopes to help IMI’s ND projects to create a platform for the efficient collaboration of current and future IMI ND projects, thus helping them to make progress and deliver results that will benefit the millions of people who live with neurodegenerative diseases.

Achievements & News

Neuronet Knowledge Base showcases 18 IMI neurodegeneration projects
February 2021

IMI’s Neuronet project has launched a Knowledge Base which brings together in one place information on 18 IMI neurodegeneration projects. The comprehensive resource is an integral part of Neuronet’s endeavour to boost collaboration across the research portfolio by identifying gaps, multiplying the portfolio’s impact, and enhancing its visibility.###

As well as providing an overview of the IMI neurodegeneration research programme through its interactive dashboard, the Knowledge Base acts as a one-stop shop to explore the diverse projects and outputs of the programme. In addition to links to over 380 publications and 350 publishable deliverable reports, the Knowledge Base includes an ‘asset map’ showing the different assets resulting from the projects, such as genetic datasets, clinical cohorts, and data platforms.

Furthermore, the Knowledge Base offers access to a regulatory, health technology assessment & payer engagement Decision Tool to help researchers identify the key processes and procedures for engagement with these stakeholders at key points in the development of an asset.

‘The Neuronet Knowledge Base tool intends to bring the “better together” team concept to life and overcome the inherent fragmentation often found in a project-based research landscape,’ said Neuronet coordinator Carlos Díaz of SYNAPSE.

Find out more

Participants Show participants on map

EFPIA companies
  • Eli Lilly And Company LTD, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
  • Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
Universities, research organisations, public bodies, non-profit groups
  • National Institute For Health And Care Excellence, Manchester, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Synapse Research Management Partners SL, Barcelona, Spain
Patient organisations
  • Alzheimer Europe, Luxembourg, Luxembourg
Associated partners
  • Parkinson'S Disease Society Of Theunited Kingdom Lbg, London, United Kingdom
Project Leader
Lennert Steukers